This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;7(3):e2100.
doi: 10.1371/journal.pntd.0002100. Epub 2013 Mar 14.

Impact of community-based lymphedema management on perceived disability among patients with lymphatic filariasis in Orissa State, India

Affiliations

Impact of community-based lymphedema management on perceived disability among patients with lymphatic filariasis in Orissa State, India

Philip J Budge et al. PLoS Negl Trop Dis. 2013.

Abstract

Background: Lymphatic filariasis (LF) infects approximately 120 million people worldwide. As many as 40 million have symptoms of LF disease, including lymphedema, elephantiasis, and hydrocele. India constitutes approximately 45% of the world's burden of LF. The Indian NGO Church's Auxiliary for Social Action (CASA) has been conducting a community-based lymphedema management program in Orissa State since 2007 that aims to reduce the morbidity associated with lymphedema and elephantiasis. The objective of this analysis is to evaluate the effects of this program on lymphedema patients' perceived disability.

Methodology/principal findings: For this prospective cohort study, 370 patients ≥14 years of age, who reported lymphedema lasting more than three months in one or both legs, were recruited from villages in the Bolagarh sub-district, Khurda District, Orissa, India. The World Health Organization Disability Assessment Schedule II was administered to participants at baseline (July, 2009), and then at regular intervals through 24 months (July, 2011), to assess patients' perceived disability. Disability scores decreased significantly (p<0.0001) from baseline to 24 months. Multivariable analysis using mixed effects modeling found that employment and time in the program were significantly associated with lower disability scores after two years of program involvement. Older age, female gender, the presence of other chronic health conditions, moderate (Stage 3) or advanced (Stage 4-7) lymphedema, reporting an adenolymphangitis (ADL) episode during the previous 30 days, and the presence of inter-digital lesions were associated with higher disability scores. Patients with moderate or advanced lymphedema experienced greater improvements in perceived disability over time. Patients participating in the program for at least 12 months also reported losing 2.5 fewer work days per month (p<0.001) due to their lymphedema, compared to baseline.

Significance: These results indicate that community-based lymphedema management programs can reduce disability and prevent days of work lost. These effects were sustained over a 24 month period.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Map of India.
The location of Orissa state (shaded gray) and Khurda District (shaded black) are indicated.
Figure 2
Figure 2. Mean WHO-DAS II disability scores by domain.
Scores for each domain are shown as labeled; total disability is shown in the lowest panel.
Figure 3
Figure 3. Total perceived disability scores.
Total WHO DAS II scores (composite of all 6 domains) are shown prior to enrollment and 24 months after enrollment in the lymphedema management program, by lymphedema stage category.
Figure 4
Figure 4. Reported days work lost.
Self-report of the mean number of days of work lost due to lymphedema-related disability in the past 30 days. Error bars represent 95% confidence intervals around the mean. All times were significantly different from baseline (time 0).

References

    1. WHO (2008) Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 83: 333–341. - PubMed
    1. WHO (2007) Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 82: 361–380. - PubMed
    1. Addiss D (2010) The Global Alliance to Eliminate Lymphatic Filariasis (2010) The 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis: A half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parsit Vectors 3: 100. - PMC - PubMed
    1. Kumari AK, JY, Das LK (2012) Issues in delivering morbidity management for lymphatic filariasis elimination: a study in Pondicherry, South India. Scientific World Journal 2012: 1–6. - PMC - PubMed
    1. Dreyer G, Addiss D, Dreyer P, Noroes J (2002) Basic Lymphoedema Management: Treatment and Prevention of Problems Associated with Lymphatic Filariasis. Hollis, NJ: Hollis Pub Co.124 p.

Publication types

Cite

AltStyle によって変換されたページ (->オリジナル) /